FDA Approval Insights: Avapritinib in Indolent Systemic Mastocytosis
0
0
0 ビュー·
07/10/23
Dr Gotlib discusses the significance of the FDA approval of avapritinib in indolent systemic mastocytosis, key findings from the PIONEER trial, and the quality of life benefits that avapritinib provides for patients in this population.
もっと見せる
0 コメント
sort 並び替え